MenAfriNet

In October 2013, the Bill & Melinda Gates Foundation awarded a grant to establish a regional meningitis surveillance network in sub-Saharan Africa—MenAfriNet—to monitor the impact of the meningococcal A conjugate vaccine (MACV/PsA­­–TT; MenAfriVac™ Serum Institute of India, Ltd). The CDC Foundation and the U.S. Centers for Disease Control and Prevention (CDC), in partnership with the World Health Organization-Regional Office for Africa (WHO-AFRO), the Agence de Médicine Préventive (AMP), and other non-governmental agencies with expertise in meningitis surveillance in the region, formed an international consortium to provide Ministries of Health with technical support to build in-country laboratory and epidemiologic capacity for implementing and sustaining case-based meningitis surveillance. The information provided from MenAfriNet case-based meningitis surveillance will support ongoing evaluation of MACV performance, monitoring disease trends of non-A serogroups, as well as inform future vaccine program decisions.

Vision

To establish a regional meningitis case-based surveillance network to support decisions about new meningitis vaccine introduction across sub-Saharan Africa.

Mission

To leverage existing surveillance capacity in the region to gather high quality data to answer critical questions about MACV while also achieving the secondary objective of stronger, sustainable systems that will enable continued monitoring of meningitis epidemiology in the region after this project concludes.